The ART-SCORE is not an effective tool for optimizing patient selection for DEB-TACE retreatment. A multicentre Spanish study

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Pipa-Muniz, M
  • Castells, L
  • Pascual, S
  • Fernandez-Castroagudin, J
  • Diez-Miranda, I
  • Irurzun, J
  • Senosiain, M
  • Arenas, J
  • de la Mata, M
  • Turnes, J
  • Monge-Romero, MI
  • Bustamante-Schneider, J
  • Otegui, N
  • Molina-Perez, E
  • Rodriguez-Menendez, JE
  • Varela, M

Grupos

Abstract

Introduction: The appropriate selection of hepatocellular carcinoma (HCC) patients who are eligible for transarterial chemoembolization (TACE) remains a challenge. The ART score has recently been proposed as a method of identifying patients who are eligible or not for a second TACE procedure. Objective: To assess the validity of the Assessment for Retreatment with TACE (ART) score in a cohort of patients treated with drug-eluting bead TACE (DEB-TACE). Secondary objective: to identify clinical determinants associated with overall survival (OS). Method: A retrospective, multicentre study conducted in Spain in patients with HCC having undergone two or more DEB-TACE procedures between January 2009 and December 2014. The clinical characteristics and OS from the day before the second DEB-TACE of patients with a high ART score (ART >= 2.5) and a low ART score (ART 0-1) were compared. Risk factors for mortality were identified using Cox's proportional hazards model. Results: Of the 102 patients included, 51 scored 0-1.5 and 51 scored >= 2.5. Hepatitis C was more frequent in patients scoring >= 2.5. Median OS from the day before the second DEB-TACE was 21 months (95% CI, 15-28) in the group scoring 0-1.5, and 17 months (95% CI, 10-25) in the group scoring >= 2.5 (P=0.3562). Platelet count and tumour size, but not the ART score, were independent baseline predictors of OS. Conclusions: The ART score is not suitable for guiding DEB-TACE retreatment according to Spanish clinical practice standards. (C) 2017 Elsevier Espana, S.L.U., AEEH y AEG. All rights reserved.

Datos de la publicación

ISSN/ISSNe:
0210-5705, 0210-5705

Gastroenterologia y Hepatologia  ELSEVIER ESPANA SLU

Tipo:
Article
Páginas:
515-524
PubMed:
28676199
Factor de Impacto:
0,218 SCImago ℠
Cuartil:
Q3 SCImago ℠

Citas Recibidas en Web of Science: 7

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Hepatocellular; carcinoma; Transarterial liver; chemoembolization; Liver neoplasm; Retrospective study; Survival rate

Campos de Estudio

Compartir